scholarly journals THE OPTIMIZATION OF DIALYSIS PROGRAM FOR UREMIC POLYNEUROPATHY TREATMENT

2014 ◽  
Vol 5 (1) ◽  
pp. 12-16
Author(s):  
A N Fedoseev ◽  
V V Shestakov ◽  
I N Vaulin ◽  
A S Vaulina ◽  
V V Smirnov ◽  
...  

The impact of changes dialysis program on ENMG rates in patients with a terminal stage of chronic renal insufficiency receiving regular dialysis treatment was studied. The study made it possible to determine that the strengthening of the dialysis program with the increase in KT/V to 1.4 promotes regression of neurological manifestations of uremic polyneuropathy and improvement of neurophysiological indicses of functioning of the peripheral nerves in patients with a terminal stage of chronic renal insufficiency. Significantly improved indicators of functional activity as axial cylinders of the peripheral nerves and the myelin sheath. Optimisation of dialysis program allows to improve the functional activity of peripheral nerves already by the end of the first month, the maximum therapeutic effect at 6month treatment and to obtain the steadfast compensation sensory and motor deficit of uremic polyneuropathy. Thus, for the correction of uremic polyneuropathy it is expedient to strengthen the dialysis program with the increase in KT/V to 1.4.

1996 ◽  
Vol 16 (2) ◽  
pp. 158-162 ◽  
Author(s):  
Marion Haubitz ◽  
Reinhard Brunkhorst ◽  
Eike Wrenger ◽  
Peter Froese ◽  
Matthias Schulze ◽  
...  

Objective Evaluation of the inflammatory activity in patients on chronic peritoneal dialysis (PD) and patients on chronic hemodialysis (HD) in comparison to patients with chronic renal insufficiency without dialysis treatment and healthy volunteers. Design Open, non randomized prospective study. Setting Nephrology Department, including HD and PD therapy in a university hospital. Patients Twenty -four patients on chronic PD, 21 patients on chronic HD therapy using a cuprophan dialyzer, 16 patients with chronic renal insufficiency without dialysis treatment, and 33 healthy volunteers; 8 additional patients before and after initiation of chronic HD therapy. All patients and controls were without infection or immunosuppressive therapy. Main Outcome Measures As a marker of the inflammatory activity in the different patient groups, C-reactive protein (CAP) was measured serially using a sensitive, enzyme-Iinked, immunosorbent assay in order to detect values below the detection limit of standard assays. Results All patient groups had CAP levels higher than the normal controls (p < 0.01). Patients on HD had CAP levels significantly higher than PD patients (p < 0.01) whose levels were comparable to patients without dialysis therapy. Accordingly, longitudinal measurements before and after initiation of chronic HD showed a significant increase in CAP levels after the beginning of HD treatment (p < 0.04). Conclusions The results suggest that induction of the inflammatory activity is lower during PD compared to HD, since stimulation by the dialyzer membrane, dialysate buffer, or bacterial fragments in the dialysate is avoided. This observation might indicate a possible lower risk of long-term complications in patients with PD.


2004 ◽  
Vol 35 (2) ◽  
pp. 67-73
Author(s):  
Nela Rašeta ◽  
Milenko Kulauzov ◽  
Sanja Avram-Šolaja ◽  
Biljana Jakovljević

1999 ◽  
Vol 5 (3) ◽  
pp. 70
Author(s):  
Sohail Hassan ◽  
Steven Borzak ◽  
Edward F. Philbin ◽  
Sandeep Soman ◽  
Shalin Shah ◽  
...  

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Roxana Mehran ◽  
Ajay J Kirtane ◽  
George D Dangas ◽  
E. M Ohman ◽  
Stuart Pocock ◽  
...  

Background: In the ACUITY Trial, patients (pts) with chronic renal insufficiency (CRI) had significantly higher rates of ischemic events and major bleeding compared to pts without CRI at 30 days. Bivalirudin (Biv) monotherapy provided similar protection from ischemic events but with significantly less bleeding compared to heparin + a GPIIb/IIIa inhibitor (Hep+GPI). The impact of a Biv alone strategy on one year mortality is unknown. Methods: Pts with moderate and high risk acute coronary syndromes (ACS) were randomized to Hep + GPI, Biv + GPI, or Biv monotherapy. CRI was defined as baseline creatinine clearance (CrCl) <60 mL/min. We evaluated the impact of CRI and antithrombotic strategy on composite ischemia (death, MI, or revascularization) and mortality at one year. Results: Of the pts enrolled, 12,933 had baseline CrCl data: 2468 (19.1%) pts had CrCl ≥60 mL/min and 10,465 (80.9%) pts had CrCl <60 mL/min. Rates of major bleeding at 30 days in pts with CRI were significantly lower with Biv alone vs Hep+GPI (6.2% vs 9.8%, p<0.01). Pts with CRI had higher mortality at one year compared to those without CRI (8.7% vs 3.0%, p<0.001). There was no difference in composite ischemia for pts who received Biv monotherapy vs Hep + GPI (23.0% vs 21.4%, p=0.10). One year mortality by antithrombin strategy is shown in the Figure . Conclusions: CRI in pts with ACS is associated with higher rates of one year mortality. In these high risk pts, Biv monotherapy improved early clinical outcomes compared to Hep + GPI by reducing major bleeding, and resulted in similar rates of one year mortality. Cumulative Mortality at One Year, Patients with CRI


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3776-3776
Author(s):  
Dolores Puente ◽  
Cecilia Colorio ◽  
Roxana Ratto ◽  
Martin Descalzo ◽  
Andrea Rossi ◽  
...  

Abstract Previous studies have shown that anemia is frequently associated with higher morbidity and mortality in HF pts. Our aim was to determine the impact of anemia in pts hospitalized with congestive HF at our hospital. We analyzed data from 277 pts with diagnosis of HF admitted between 1 June 2004 and 31 December 2005, with a follow up of at least 6 months. Anemia was defined as hemoglobin (Hb) &lt;11,5 g/dl. HF was classified according to Framingham criteria. Previous history of arterial hypertension, diabetes, dislipemia, chronic renal insufficiency and ACE inhibitors treatment was recorded. Ischaemic and non- ischaemic etiology of cardiopathy was established. Renal disfunction was defined as creatinin concentraction &gt;1.9 mg/dl. Pts with HF were assigned to group A (with anemia) or B (control). Statistical analysis was performed using Pearson’s Chi square, Spearman’s rho, Fisher test and Kaplan Meyer survival function. Results: We evaluated 229 (82,7%) pts with a median follow up of 594 days (range: 1–1129 days). Mean age was 68,02 years (median 71, range: 17–91). 143/229 (62,4%) were male. In 75 /229 (32.75%) cases a Hb &lt; 11,5 g/dl was measured at admission. The mean Hb was 13,1 g/dl for the entire group. Anemia pts showed a mean Hb of 10.6 g/dl. Demographic, clinical and outcome features are shown in table 1.Group A showed a higher number of readmissions because of HF and other cardiac. Conclussions: In our analysis the prevalence of anemia was 33% in pts hospitalized for HF. There was no significant differences among clinical variables between anemic and non-anemic pts. Anemia was associated with worse clinical outcome (Group A pts required more readmissions for HF and other cardiological causes)and all cause mortality. Mean survival was longer in Group B pts.according to Kaplan Meyer analysis. TABLE 1: RESULTS GROUP A (n=75) GROUP B (n= 154) p Male 42 (56%) 101 (65.5%) Mean age (years) 70.38 (R:20–90) 67.1 (R:17–91) Mean Hb (g/dl) 10.6 14.3 Ischaemic cardiopathy 38(50,6%) 78(50.6%) Non ischaemic cardiopathy 41(54,6%) 78 Arterial hypertension 54(72%) 106(68.8%) Diabetes 24(32%) 33(21.4%) Dislipaemia 35(46.6%) 64(41.5%) Chronic renal insufficiency 18(24%) 19(12.3%) 0.03 Previous ACE inhibitors treatment 25(33%) 71(46%) 0.08 Acute pulmonary edema 12(16%) 15(9.7%) Creatinin concentration &gt; 1.9 mg/dl 16(21.3%) 18 (11.6%) Hospitalization days (mean) 9.6 (R: 1–51) 8.1(R:1–59) Readmission for HF 37 190 0.001 Readmission for other cardiologic causes 20 109 0.017 Readmission for non cardiologic diseases 18 58 Mean survival (days) 499 (R:1–1091) 658 (r=1–1129) 0.166 Global mortality 25 (33%) 32(21%) 0.05 HF related mortality 13 (20.9%) 24 (14.3%) Figure Figure


2005 ◽  
Vol 9 (1) ◽  
pp. 102-102
Author(s):  
Ismagilov R.Z. ◽  
Bapiev T.A. ◽  
Zainalov A.K. ◽  
Shynybaev T.B. ◽  
Rahimbekov T.I. ◽  
...  

2018 ◽  
Vol 71 (2) ◽  
Author(s):  
Yi-Wenn Yvonne Huang ◽  
Alison Alleyne ◽  
Vivian Leung ◽  
Michael Chapman

<p><strong>ABSTRACT</strong></p><p><strong>Background: </strong>Extended-spectrum ß-lactamase (ESBL)–producing Enterobacteriaceae are pathogens that are implicated in urosepsis and may be associated with greater morbidity and mortality than non-ESBL Enterobacteriaceae. Identification of risk factors for ESBL infection may facilitate the selection of appropriate empiric therapy.</p><p><strong>Objectives: </strong>The primary objectives were to determine the cumulative incidence of ESBL urosepsis, to identify major risk factors for ESBL urosepsis, and to determine the impact of international travel on development of ESBL urosepsis in an ethnically diverse Canadian population. The secondary objective was to characterize the outcomes of patients with ESBL urosepsis.</p><p><strong>Methods: </strong>A single-centre retrospective nested case–control study was conducted from January 2011 to June 2013. The study cohort consisted of adult patients with urosepsis and positive results on blood culture for ESBL-producing and non–ESBL-producing Enterobacteriaceae. Multivariate analysis was then used to determine risk factors for ESBL urosepsis.</p><p><strong>Results: </strong>The cumulative incidence of ESBL urosepsis at the study site was 19.4% (58/299) over 2.5 years. The 58 cases of ESBL urosepsis were compared with 118 controls (patients with urosepsis caused by non-ESBL Enterobacteriaceae). Significant predictors of ESBL urosepsis were chronic renal insufficiency (odds ratio [OR] 4.66, 95% confidence interval [CI] 1.96–11.08; <em>p </em>&lt; 0.001) and travel to an endemic region in the previous 6 months (OR 4.62, 95% CI 1.17–18.19; <em>p </em>= 0.029), as well as Punjabi or Hindi as the primary language (OR 3.25, 95% CI 1.45–7.29; <em>p </em>= 0.004) and male sex (OR 2.65, 95% CI 1.21–5.80; <em>p </em>= 0.015). Patients with ESBL urosepsis had worse prognosis—in terms of death or discharge with palliative measures only—than those with non-ESBL urosepsis (7/58 [12.1%] versus 4/118 [3.4%]; <em>p </em>= 0.042).</p><p><strong>Conclusions: </strong>Institution-specific data support prompt recognition of patients at risk for ESBL infections. Chronic renal insufficiency, recent travel to regions endemic for ESBL-producing organisms, primary language of Punjabi or Hindi, and male sex were the strongest risk factors for ESBL urosepsis at the study centre. However, findings from this single-centre study may not be generalizable to other institutions.</p><p><strong>RÉSUMÉ</strong></p><p><strong>Contexte : </strong>Les entérobactériacées productrices de ß-lactamases à spectre étendu (BLSE) sont des pathogènes en cause dans les cas d’urosepsie et peuvent être associées à des taux de morbidité et de mortalité supérieurs à ceux liés aux entérobactériacées ne produisant pas de BLSE. L’identification des facteurs de risque pour l’infection à BLSE pourrait faciliter le choix d’une antibiothérapie empirique appropriée.</p><p><strong>Objectifs : </strong>Les objectifs principaux étaient de déterminer l’incidence cumulative des cas d’urosepsie à BLSE, d’identifier les facteurs de risqué importants d’urosepsie à BLSE et de découvrir les effets des voyages à l’étranger sur l’apparition d’urosepsie à BLSE dans une population multiethnique canadienne. L’objectif secondaire était d’offrir un portrait de l’issue des patients atteints d’urosepsie à BLSE.</p><p><strong>Méthodes : </strong>Une étude cas-témoins emboîtée rétrospective a été menée dans un seul centre entre janvier 2011 et juin 2013. La cohorte était composée de patients adultes atteints d’urosepsie dont les résultats d’hémoculture étaient positifs pour des entérobactériacées produisant des BLSE ou pour des entérobactériacées ne produisant pas de BLSE. Une analyse multivariée a ensuite été utilisée afin de discerner les facteurs de risque pour l’urosepsie à BLSE.</p><p><strong>Résultats : </strong>L’incidence cumulative des cas d’urosepsie à BLSE dans l’établissement à l’étude était de 19,4 % (58/299) sur 2,5 ans. Les 58 cas d’urosepsie à BLSE ont été comparés à 118 témoins (des patients atteints d’urosepsie causée par des entérobactériacées ne produisant pas de BLSE). Les meilleures variables explicatives d’urosepsie à BLSE étaient : l’insuffisance rénale chronique (risque relatif approché [RRA] de 4,66, intervalle de confiance [IC] à 95 % de 1,96–11,08; <em>p </em>&lt; 0,001) et les voyages dans une région endémique au cours des six derniers mois (RRA de 4,62, IC à 95 % de 1,17–18,19; <em>p </em>= 0,029) ainsi que le punjabi ou l’hindi comme langue principale (RRA de 3,25, IC à 95 % de 1,45–7,29; <em>p </em>= 0,004) et le sexe masculin (RRA de 2,65, IC à 95 % de 1,21–5,80; <em>p </em>= 0,015). Les patients atteints d’urosepsie à BLSE présentaient un pronostic plus sombre – en ce qui touche le décès ou le congé avec pour seule prescription des mesures palliatives – que ceux atteints d’urosepsie causée par des entérobactériacées non productrices de BLSE (7/58 [12,1 %] contre 4/118 [3,4 %], <em>p </em>= 0,042).</p><strong>Conclusions : </strong>Des données propres à l’établissement incitent à dépister rapidement les patients à risque d’infection à BLSE. L’insuffisance rénale chronique, les voyages récents dans des régions où les organismes producteurs de BLSE sont endémiques, le punjabi ou l’hindi comme langue principale et le sexe masculin représentaient les facteurs de risques les plus importants pour l’urosepsie à BLSE au centre à l’étude. Cependant, il se pourrait que les résultats provenant de la présente étude réalisée dans un seul centre ne puissent pas être généralisés à d’autres établissements.


Sign in / Sign up

Export Citation Format

Share Document